Studies with follow-up of 2 to 6 years show that corneal crosslinking for progressive keratectasia is safe and induces long-term structural changes.
Data showed that CXL results in a significant keratometric flattening effect that is stable in most eyes, while causing minimal complications or significant best spectacle-corrected visual acuity (BSCVA) loss, noted Prof. Seiler, professor of ophthalmology, University of Zurich, and chairman, IROC Zurich, Switzerland.
Breaking News: FDA approves perfluorohexyloctane ophthalmic solution for dry eye disease
May 18th 2023According to Bausch + Lomb and Novaliq, MIEBO is the first prescription eye drop approved for dry eye disease that directly targets tear evaporation, based on consistent results from a pair of pivotal Phase 3 trials.
2 Clarke Drive
Cranbury, NJ 08512